Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

- PMLiVE

Boehringer launches iPhone app for patients on Gilotrif

App offers treatment guide for those taking its cancer drug

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

Teva Pharma logo

Teva hit with $1.2bn pay-for-delay fine

Federal Trade Commission continues its tough stance against generic blocking

- PMLiVE

Novartis and Google to fund ‘robotic pill’ maker

Firms sign up to Rani Therapeutics’ new drug delivery system

- PMLiVE

Sanofi pays $245m for FDA priority review voucher

PRV reduces review time from ten to six months

Lilly backs Bluetooth insulin device and app firm

Invests in San Diego-based medical device company Companion Medical

- PMLiVE

FDA approves two new IBS medicines

US regulator gives the nod to Actavis’ and Salix’ bowel drugs

UK Life Sciences Strategy - one year on

Express Scripts pushes for pay-for-performance in cancer

States it is the only way to fund the growing cost of cancer care

- PMLiVE

Huntingdon Life Sciences appoints Joseph Bedford

He will serve as the firm's corporate VP forglobal strategic marketing

Sanofi reception

Sanofi licenses cardiovascular therapy in South Korea

Phase III drug comes from Swedish company NeuroVive

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links